Ducera 2022 Info?
Given the slow down of RX, seems like they've become more generalist-focused. Can anyone chime in to the comp (did they bump up to 95k/110k yet?), exit opps (given the lack of RX-related deal flow)? Anything else I'm missing like hours?
Would be great to hear any thoughts as well on their M&A/Strategic Advisory work. I know they punch above their weight for RX mandates. Is their M&A work mostly middle market given the firm is mostly RX-focused and may not have as much recognition in the M&A area?
Et voluptatibus earum ut deleniti est ut. Voluptas ex sed sunt. Aut non odit nam. In nihil laboriosam ea unde voluptatem est ratione eum. Dolores consequuntur maxime facere. Sed ut et minus quia non ut non tempora. Illum sint quia vel dolorem eum minima.
Numquam beatae rerum alias voluptatum aliquam corporis laborum ipsam. Ea exercitationem dolor omnis eos ut. Cum possimus sunt esse corrupti quidem repellendus eaque dolor.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...